GlassScriptPhysician profile
Muhammad Nasir Ali
NPI 1346221264
$5,886.51
in general payments reported to CMS, 2019-2025
34 companies · $376 in 2025
The $376 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $761 · 2020: $1,113 · 2021: $1,876 · 2022: $824 · 2023: $382 · 2024: $555 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,312.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $792.82 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $665.03 | 2019-2025 | Ofev |
| Glaxosmithkline, LLC. | $628.82 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $479.49 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $454.78 | 2019-2025 | Farxiga |
| Amgen INC. | $425.84 | 2020-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $303.62 | 2019-2021 | |
| Cumberland Pharmaceuticals, INC. | $284.32 | 2019-2022 | |
| Lilly USA, LLC | $244.34 | 2020-2023 | Jardiance, Mounjaro |
| Novo Nordisk INC | $209.56 | 2019-2025 | Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $138.96 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.65 | 2021-2025 | Xifaxan |
| Abbvie INC. | $118.76 | 2021-2023 | Creon, Linzess, Viberzi |
| Hikma Pharmaceuticals USA | $115.27 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $111.16 | 2021-2025 | Gvoke Hypopen |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $108.83 | 2021 | |
| Merck Sharp & Dohme LLC | $107.33 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $93.17 | 2019-2022 | |
| Dexcom, INC. | $61.96 | 2024-2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $52.27 | 2021-2024 | Zoryve |
| Esperion Therapeutics, INC. | $49.05 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.75 | 2021-2022 | |
| Shionogi INC | $45.44 | 2022-2024 | Fetroja |
| Janssen Pharmaceuticals, INC | $40.56 | 2019-2021 | |
| Exact Sciences Corporation | $31.59 | 2024 | Cologuard Collection Kit |
| Shield Therapeutics INC | $22.11 | 2023 | Accrufer |
| Mylan Specialty L.P. | $20.88 | 2021 | |
| Evoke Pharma, INC. | $19.00 | 2021 | |
| Bardy Diagnostics, INC. | $18.00 | 2021 | |
| Verona Pharma, INC. | $17.71 | 2025 | Ohtuvayre |
| Vifor Pharma, INC. | $15.89 | 2024 | Veltassa |
| Ironwood Pharmaceuticals, INC | $15.27 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.39 | 2019 | |
| Allergan, INC. | $11.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.